An estimated 71 million people worldwide live with chronic hepatitis C virus (HCV) infection which, if left untreated, can increase morbidity and mortality. Direct-acting antivirals (DAAs) are curative treatments for HCV. However, initiation of these treatments depends on access to health care and physicians that can diagnose and initiate treatment.
The COVID-19 pandemic resulted in restrictions to healthcare services in March 2020. Delays in diagnosis and interruptions in care lead to patients being lost to follow-up, producing negative health outcomes and ongoing transmission.
The following maps examine trends in HCV DAA medication prescribing and the average distance to a prescriber by public health unit in Ontario in 2019.
For further details regarding this analysis, read through the key findings below:
Additional related research conducted by the ODPRN: